DK3319609T3 - Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer - Google Patents
Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer Download PDFInfo
- Publication number
- DK3319609T3 DK3319609T3 DK16822054.9T DK16822054T DK3319609T3 DK 3319609 T3 DK3319609 T3 DK 3319609T3 DK 16822054 T DK16822054 T DK 16822054T DK 3319609 T3 DK3319609 T3 DK 3319609T3
- Authority
- DK
- Denmark
- Prior art keywords
- compositions
- methods
- drug combinations
- antibacterial drug
- antibacterial
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562190588P | 2015-07-09 | 2015-07-09 | |
| PCT/US2016/041565 WO2017008034A1 (en) | 2015-07-09 | 2016-07-08 | Compositions and methods of use of antibacterial drug combinations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3319609T3 true DK3319609T3 (da) | 2022-08-22 |
Family
ID=57686086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16822054.9T DK3319609T3 (da) | 2015-07-09 | 2016-07-08 | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10500191B2 (da) |
| EP (2) | EP4112057A1 (da) |
| JP (3) | JP6845511B2 (da) |
| CN (2) | CN108289896B (da) |
| DK (1) | DK3319609T3 (da) |
| ES (1) | ES2929058T3 (da) |
| HK (1) | HK1258393A1 (da) |
| PL (1) | PL3319609T3 (da) |
| PT (1) | PT3319609T (da) |
| WO (1) | WO2017008034A1 (da) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6845511B2 (ja) | 2015-07-09 | 2021-03-17 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 抗細菌性薬剤併用物の組成物及び使用方法 |
| CN107789355B (zh) * | 2016-09-07 | 2022-04-12 | 湘北威尔曼制药股份有限公司 | 含有哌拉西林的复方药物组合物及其应用 |
| US10434089B2 (en) | 2017-01-25 | 2019-10-08 | The Johns Hopkins University | Avibactam and carbapenems antibacterial agents |
| US11690810B2 (en) * | 2018-11-14 | 2023-07-04 | The Chinese University Of Hong Kong | Combination treatment of bacterial infection |
| CN110279692A (zh) * | 2019-07-17 | 2019-09-27 | 中南大学湘雅二医院 | 一种抗感染组合物、制剂及其应用 |
| GB202100378D0 (en) * | 2021-01-12 | 2021-02-24 | Quadram Inst Bioscience | Methods and compositions for antibiotic potentiation |
| CN113559099A (zh) * | 2021-08-27 | 2021-10-29 | 丹诺医药(苏州）有限公司 | 包含舒巴坦和阿维巴坦的药物组合物及其应用 |
| CN117940127A (zh) * | 2022-07-05 | 2024-04-26 | 塞戈瑞·弗拉基米罗维奇·西多连科 | 治疗多种耐药细菌感染的制剂 |
| CN115778949A (zh) * | 2022-12-15 | 2023-03-14 | 复旦大学附属华山医院 | 用于抑制产kpc酶肺炎克雷伯菌的组合物、药物及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1565456A (zh) * | 2003-06-14 | 2005-01-19 | 张哲峰 | 一种头孢吡肟抗菌组合药物 |
| EP2167081B1 (en) * | 2007-05-21 | 2013-06-26 | Hans Rudolf Pfaendler | Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems |
| US20100197650A1 (en) * | 2008-08-28 | 2010-08-05 | Forest Laboratories Holdings Ltd. | Compositions and methods of treatment comprising ceftaroline |
| CN102349897B (zh) * | 2011-07-22 | 2012-12-26 | 深圳市新泰医药有限公司 | 一种美罗培南钠/他唑巴坦钠药物组合物 |
| EP2768503A1 (en) | 2011-07-26 | 2014-08-27 | Wockhardt Limited | Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor |
| WO2013085152A1 (en) * | 2011-12-07 | 2013-06-13 | Union Korea Pharm Co., Ltd. | Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors |
| NZ706734A (en) | 2012-09-03 | 2016-05-27 | Wockhardt Ltd | Pharmaceutical compositions useful for the treatment or control of bacterial infections |
| GB201306980D0 (en) * | 2013-04-17 | 2013-05-29 | Blueberry Therapeutics Ltd | Methods |
| CA2983992A1 (en) | 2015-04-30 | 2016-11-03 | The Regents Of The University Of Colorado, A Body Corporate | Polycyclic indoline and indolenine compounds |
| JP6845511B2 (ja) | 2015-07-09 | 2021-03-17 | ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 抗細菌性薬剤併用物の組成物及び使用方法 |
| WO2017203266A1 (en) | 2016-05-25 | 2017-11-30 | Entasis Therapeutics Limited | Combination therapy for treatment of resistant bacterial infections |
-
2016
- 2016-07-08 JP JP2018521191A patent/JP6845511B2/ja active Active
- 2016-07-08 CN CN201680052323.2A patent/CN108289896B/zh active Active
- 2016-07-08 CN CN202210119650.2A patent/CN114796499A/zh active Pending
- 2016-07-08 EP EP22176825.2A patent/EP4112057A1/en active Pending
- 2016-07-08 PL PL16822054.9T patent/PL3319609T3/pl unknown
- 2016-07-08 WO PCT/US2016/041565 patent/WO2017008034A1/en active Application Filing
- 2016-07-08 PT PT168220549T patent/PT3319609T/pt unknown
- 2016-07-08 US US15/743,203 patent/US10500191B2/en active Active
- 2016-07-08 DK DK16822054.9T patent/DK3319609T3/da active
- 2016-07-08 EP EP16822054.9A patent/EP3319609B1/en active Active
- 2016-07-08 ES ES16822054T patent/ES2929058T3/es active Active
-
2019
- 2019-01-17 HK HK19100800.9A patent/HK1258393A1/zh unknown
- 2019-10-29 US US16/667,227 patent/US11559514B2/en active Active
-
2021
- 2021-02-10 JP JP2021019647A patent/JP7121954B2/ja active Active
-
2022
- 2022-07-28 JP JP2022120438A patent/JP2022141948A/ja active Pending
- 2022-12-08 US US18/063,454 patent/US20230293488A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2929058T3 (es) | 2022-11-24 |
| CN108289896B (zh) | 2022-03-01 |
| JP7121954B2 (ja) | 2022-08-19 |
| US11559514B2 (en) | 2023-01-24 |
| JP2021075560A (ja) | 2021-05-20 |
| PT3319609T (pt) | 2022-08-23 |
| JP2022141948A (ja) | 2022-09-29 |
| JP2018525434A (ja) | 2018-09-06 |
| US20180200226A1 (en) | 2018-07-19 |
| EP4112057A1 (en) | 2023-01-04 |
| CN114796499A (zh) | 2022-07-29 |
| PL3319609T3 (pl) | 2022-12-05 |
| EP3319609A1 (en) | 2018-05-16 |
| JP6845511B2 (ja) | 2021-03-17 |
| US20200054605A1 (en) | 2020-02-20 |
| WO2017008034A1 (en) | 2017-01-12 |
| US10500191B2 (en) | 2019-12-10 |
| EP3319609A4 (en) | 2018-12-12 |
| US20230293488A1 (en) | 2023-09-21 |
| HK1258393A1 (zh) | 2019-11-08 |
| EP3319609B1 (en) | 2022-06-15 |
| CN108289896A (zh) | 2018-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3386484T3 (da) | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler | |
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3317284T3 (da) | Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse | |
| DK3234133T3 (da) | Crispr-baserede sammensætninger og fremgangsmåder til anvendelse | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3212778T3 (da) | Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser | |
| DK3144001T3 (da) | Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3393655T3 (da) | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme | |
| KR20180084891A (ko) | 구조 조성물 및 방법 | |
| DK3319609T3 (da) | Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| DK3288553T3 (da) | Kombinationer af cannabinoider og n-acylethanolaminer | |
| DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
| DK3102555T3 (da) | Sammensætninger af forbindelser og anvendelser deraf | |
| DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
| DK3394065T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf | |
| DK3209696T3 (da) | Fremgangsmåder og sammensætninger til diagnosticering og behandling af glioblastom | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3261644T3 (da) | Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
| DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
| DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
| DK3265126T3 (da) | Kombinationsformulering af tesofensin og metoprolol |